Sponsors (10)
Ask me to break this bill down.
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Requires infant formula makers to quickly notify the Secretary of Health and Human Services (FDA) when finished-product testing confirms certain harmful microorganisms, to cooperate on isolating or stopping distribution of affected batches, and to provide test data and investigation records for inspection. Directs the Secretary to complete a confirmation review within 90 days and adds recurring reporting, supply‑chain updates to specific congressional committees, and stakeholder-engaged assessments at 1, 3, and 5 years to improve infant formula safety and supply resilience.
Make three small textual edits to paragraph (1) of Section 412(e): (A) strike a semicolon, (B) insert text after a semicolon, and (C) replace the phrase "the infant formula" with "an infant formula".
Redesignate existing paragraph (2) of Section 412(e) as paragraph (5).
If testing of a sample from any production aggregate of finished infant formula is confirmed positive for any microorganism for which finished product testing is required under 21 CFR 106.55(e) (or any successor regulation), the manufacturer must notify the Secretary of that confirmed positive analytical result.
The manufacturer must, within 1 business day of acquiring a confirmed positive analytical result, notify the Secretary of such result, regardless of whether the product has left an establishment subject to the manufacturer's control.
After a confirmed positive analytical result, the manufacturer must promptly consult with the Secretary for proper isolation of the affected product and, as the Secretary may require, cease distribution and properly dispose of the affected product.
Who is affected and how:
Infant formula manufacturers and manufacturing facilities: face new legal obligations to notify the Secretary of confirmed positive test results, to provide test data and isolates, to cooperate on isolating or halting distribution of affected lots, and to make investigation records available electronically and for inspection. These duties may increase compliance, testing, recordkeeping, and potential product-hold actions.
Infants and families (parents/caregivers): stand to benefit from faster detection, confirmation, and regulatory action when contaminated formula is identified, which should reduce exposure risk and improve safety. Increased transparency and federal reporting may also improve public confidence.
Department of Health and Human Services / FDA and other federal agencies (including USDA): will have new responsibilities to respond quickly to notifications, complete confirmation reviews within 90 days, provide regular supply-chain reports to Congress, consult with other agencies, and produce the 1-, 3-, and 5-year assessments. This increases oversight workload and coordination duties.
Congress and oversight committees: receive regular supply-chain reporting and periodic assessments to inform oversight and potential policy responses.
Retailers and distributors: may be affected indirectly when manufacturers isolate product lots or stop distribution, potentially causing short-term supply interruptions or increased logistics and notification work.
Potential tradeoffs and effects:
Public-health benefit: faster information sharing and a defined confirmation timeline should improve the speed of recalls, product holds, and communications, reducing infant exposure to contaminated formula.
Industry burden: manufacturers may incur additional costs for enhanced documentation, data sharing, isolate preservation, and potential more-frequent production holds. Smaller producers could face proportionally larger compliance burdens.
Supply risk vs. safety gain: isolating or halting distribution of suspected lots can temporarily reduce available supply; however, the reporting and assessment requirements are designed to strengthen supply-chain resilience over time.
No explicit funding in the provided text: increased agency obligations could strain existing resources unless additional funding is provided elsewhere, potentially affecting the pace and scope of implementation.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced January 28, 2025 by Gary C. Peters · Last progress January 28, 2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 306.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute and an amendment to the title. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.